Tecan Group AG · SIX:TECN
Tecan — Jefferies HC Conference 2018
22 slides from Tecan's conference presentation, Nov 14, 2018
Slide 1: Jefferies HC Conference
Tecan Group Jefferies HC Conference DR. DAVID MARTYR, CEO NOVEMBER 14, 2018 LONDON
Slide 2: Introduction
i) & eo) > O win. xe) (e) Some —
Slide 3: Tecan's Vision Statement
Tecan’s Vision Statement Our vision is to empower every laboratory, every day, around the world with Tecan technology, products and support. We will help to shape the future of automated workflows in life sciences and clinical diagnostics through unrivaled expertise, products and customer support. 3
Slide 4: Tecan in the Center of a Dynamic Environment
Tecan in the Center of a Dynamic Environment Cell Biology Genomics Next-Gen Biobanking Sequencing Immuno Diagnostics Synthetic Biology Consumer Molecular Protein Genomics LCMS Diagnostics Sciences Applied Markets Liquid Histology …and CRISPR Biopsies Pathology many more 4
Slide 5: Introducing Tecan
Introducing Tecan • Pioneer and global leader in laboratory automation since over 35 years • Our solutions accelerate, automate and enhance the processes in state-of-the-art diagnostics and life sciences labs • Offering solutions in select application areas: • Immunoassays for specialty diagnostics
Slide 6: Tecan's Products, Business Structure and Markets
Tecan’s Products, Business Structure and Markets LIFE SCIENCES BUSINESS PARTNERINGBUSINESS PARTNERING BUSINESS • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan brand • Products sold by partners under their own through own sales & service organi
Slide 7: Revenue Profile Provides a Solid Basis
Revenue Profile Provides a Solid Basis STRONG DRIVERS ACQUISITIONS ADDING GROWING DIRECT PRESENCE IN DIAGNOSTICS NEW SOURCES IN EMERGING MARKETS OF RECURRING REVENUES Customer Segments Products Geographies 3% 21% 16% ≈ 40% ≈ 60% 21% 58% 38% 43% Research and Applied Instruments Diagnostics Europe Ser
Slide 8: Strategy and Growth Drivers
Strategy and com Growth Drivers = __,. — L . l l I I I I l I TECAN
Slide 9: Basis for Corporate Strategy: Market Structure
Basis for Corporate Strategy: Market Structure LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC PILLARS CAGR +3-5% +3-5% 1 Scale & >50 BN USD >50 BN USD capability Reagents & Consumables 3 Reagents & Consumables 2 Build additional pillars and complete portfolio 2 Instruments 3 Offer Instruments
Slide 10: New Platforms in Two Main Instrument Segments
New Platforms in Two Main Instrument Segments LIFE SCIENCES BUSINESS STRONG MARKET UPTAKE AND ORDER MOMENTUM FLUENT ® NEXT GENERATION LIQUID SPARK ®* NEXT GENERATION HANDLING PLATFORM FAMILY READER PLATFORM Setting new standards for simplicity, Greater flexibility, increased speed productivity and c
Slide 11: Growing Solutions Offering in Select Applications
Growing Solutions Offering in Select Applications LIFE SCIENCES BUSINESS LEVERAGING TECAN’S GLOBAL PRESENCE AND CUSTOMER BASE IMMUNOASSAYS FOR SPECIALTY SAMPLE PREPARATION SOLUTIONS DIAGNOSTICS FOR MASS SPECTROMETRY Building on Tecan’s long tradition in Leveraging Tecan’s leading position in mass im
Slide 12: Accelerating Broad Genomics Strategy with Acquisition of NuGEN Technologies
Accelerating Broad Genomics Strategy with LIFE SCIENCES BUSINESS Acquisition of NuGEN Technologies • Tecan further expanding dedicated solution offering in new market segment of NGS reagents • US-based NuGEN is a leading provider of innovative NGS kits and sample prep reagents, serving the fastest g
Slide 13: NGS Workflows are Composed of Multiple Steps
NGS Workflows are Composed of Multiple Steps LIFE SCIENCES BUSINESS THEY REPRESENT ABOUT HALF OF THE OVERALL USD 12BN GENOMICS MARKET Sample Extraction Library prep Library QC Sequencing Data analysis collection Broad range of The largest The fastest Check-point step Wide range of Highly fragmented
Slide 14: Partner of Choice to the IVD Industry
Partner of Choice to the IVD Industry PARTNERING BUSINESS 30+ ACTIVE INSTRUMENT ACCOUNTS, MULTIPLE DEVELOPMENTS IN PROGRESS IN REGULAR INSTRUMENTS UNDER INSTRUMENT SUPPLY PHASE RAMPING UP DEVELOPMENT PIPELINE 35+ different instruments supplied 5+ projects under 25+ concrete concepts development in d
Slide 15: Financials and Outlook
Financials and Outlook
Slide 16: Financial Highlights H1 2018
Financial Highlights H1 2018 • Strong sales growth +8.4% and +6.9% LC*; almost exclusively organic • Double-digit sales growth of +16.1% in LC in Partnering Business • Total recurring revenues at 45% of sales • Operating profit with significant increase: EBIT +26%, EBITDA +16% • Net profit also grow
Slide 17: Organic Outlook for 2018 Confirmed
Organic Outlook for 2018 Confirmed SALES DEVELOPMENT 1 ORGANIC OUTLOOK 1 FOR 2018 600 Growth in MSD range • Confirming organic outlook for 2018 given in March 575 in LC1 550 548.6 • Organic sales growth in the mid-single-digit CHF (mio) 525 506.2 percentage range in LC expected 500 475 • After signi
Slide 18: Q&A
Q&A IR IPAD APP CONTACT News, financial reports, Martin Braendle presentations, Vice President, Communications & IR videos and more Phone: +41 (0) 44 922 84 30 investor@tecan.com NEXT EVENTS 2019 www.tecan.com March 11: Full Year Results 2018 April 16: Annual Shareholder Meeting 18
Slide 19: H1 2018 Key Figures
H1 2018 Key Figures 2017 2018 Δ IN % Order Entry (in CHF mio) 290.1 298.1 +2.8% Sales (in CHF mio) 252.2 273.5 +8.4% Sales in local currencies (in CHF mio) 255.9 273.5 +6.9% Gross Profit (in CHF mio) 120.2 128.5 +6.9% in % of sales 47.7% 47.0% R&D (in CHF mio) 23.5 22.0 -6.3% in % of sales 9.3% 8.1%
Slide 20: FY 2017 Key Figures
FY 2017 Key Figures 2016 2017 Δ IN % Order Entry (in CHF mio) 503.2 564.1 +12.1% Sales (in CHF mio) 506.2 548.4 +8.3% Sales in local currencies (in CHF mio) 507.8 548.4 +8.0% Gross Profit (in CHF mio) 239.4 265.6 +11.0% in % of sales 47.3% 48.4% R&D (in CHF mio) 47.1 51.1 +8.4% in % of sales 9.3% 9.
Slide 21: > ry y
> ry y aT) with FFF j A ican | f 8 OF gf a i
Slide 22: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif